@Article{, title={Progression Free Survival Analysis of Metastatic Non-Small Cell Lung Cancer In Patients Treated with First Line Chemotherapy Regimens تحليل التقدم لسرطان الرئة ذو الخلايا غير الصغيرة النقيلي في المرضى الذين عولجوا بأنظمة العلاج الكيميائي من الخط الأول}, author={Dr. Hawraa A. K. Leelo - Professor Dr. Ahmed Mubarek Dr. Hawraa A. K. Leelo- Professor Dr. Ahmed Mubarek}, journal={Iraqi Journal of Humanitarian, Social and Scientific Research المجلة العراقية للبحوث الانسانية والاجتماعية والعلمية}, volume={1}, number={3}, pages={25-33}, year={2021}, abstract={Background: Lung cancer is the 1st cause of cancer-related death in both men and women in Iraq.Objectives: Analyze the progression-free survival of stage IV metastatic Non-Small Cell Lung Cancer (NSCLC) of Iraqi Patients who were treated with first-line chemotherapy regimens.Method: Stage IV metastatic non-small cell lung cancer of patients was followed up between September 2018 to November 2019 in Iraqi patients who were divided into two groups according to the chemotherapy regimen of treatment: 169 received first-line platinum-based chemotherapy without maintenance treatment and 54 received first-line platinum-based chemotherapy with maintenance Pemetrexed drug.Results and conclusion: Patients in this study their mean of age 61.6 years, the male has a higher incidence than a female that was 76% and 24% respectively. Adenocarcinoma histology was the most common subtype with 57.7% and squamous accounts for 42.3%. In patients who received first-line platinum-based regimen without maintenance treatment, the mean of Progression-Free Survival (PFS) was 6.3 months and the median was 5.5 months. Median PFS correlation with adenocarcinoma histology was 5 months and squamous cell carcinoma histology was 6.5 months. In patients who received an induction platinum-based regimen and followed by maintenance Pemetrexed, the mean of PFS was 5.5 months and the median of PFS was 5 months.

Background: Lung cancer is the 1st cause of cancer-related death in both men and women in Iraq.Objectives: Analyze the progression-free survival of stage IV metastatic Non-Small Cell Lung Cancer (NSCLC) of Iraqi Patients who were treated with first-line chemotherapy regimens.Method: Stage IV metastatic non-small cell lung cancer of patients was followed up between September 2018 to November 2019 in Iraqi patients who were divided into two groups according to the chemotherapy regimen of treatment: 169 received first-line platinum-based chemotherapy without maintenance treatment and 54 received first-line platinum-based chemotherapy with maintenance Pemetrexed drug.Results and conclusion: Patients in this study their mean of age 61.6 years, the male has a higher incidence than a female that was 76% and 24% respectively. Adenocarcinoma histology was the most common subtype with 57.7% and squamous accounts for 42.3%. In patients who received first-line platinum-based regimen without maintenance treatment, the mean of Progression-Free Survival (PFS) was 6.3 months and the median was 5.5 months. Median PFS correlation with adenocarcinoma histology was 5 months and squamous cell carcinoma histology was 6.5 months. In patients who received an induction platinum-based regimen and followed by maintenance Pemetrexed, the mean of PFS was 5.5 months and the median of PFS was 5 months.} }